These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 29047309)
21. Adenoviruses as vectors for delivering vaccines to mucosal surfaces. Babiuk LA; Tikoo SK J Biotechnol; 2000 Sep; 83(1-2):105-13. PubMed ID: 11000466 [TBL] [Abstract][Full Text] [Related]
22. Nonhuman Adenoviral Vector-Based Platforms and Their Utility in Designing Next Generation of Vaccines for Infectious Diseases. Alhashimi M; Elkashif A; Sayedahmed EE; Mittal SK Viruses; 2021 Jul; 13(8):. PubMed ID: 34452358 [TBL] [Abstract][Full Text] [Related]
23. Amplified and persistent immune responses generated by single-cycle replicating adenovirus vaccines. Crosby CM; Nehete P; Sastry KJ; Barry MA J Virol; 2015 Jan; 89(1):669-75. PubMed ID: 25355873 [TBL] [Abstract][Full Text] [Related]
33. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Colloca S; Barnes E; Folgori A; Ammendola V; Capone S; Cirillo A; Siani L; Naddeo M; Grazioli F; Esposito ML; Ambrosio M; Sparacino A; Bartiromo M; Meola A; Smith K; Kurioka A; O'Hara GA; Ewer KJ; Anagnostou N; Bliss C; Hill AV; Traboni C; Klenerman P; Cortese R; Nicosia A Sci Transl Med; 2012 Jan; 4(115):115ra2. PubMed ID: 22218691 [TBL] [Abstract][Full Text] [Related]
34. Chimpanzee adenovirus vector-based avian influenza vaccine completely protects mice against lethal challenge of H5N1. Cheng T; Wang X; Song Y; Tang X; Zhang C; Zhang H; Jin X; Zhou D Vaccine; 2016 Sep; 34(41):4875-4883. PubMed ID: 27576071 [TBL] [Abstract][Full Text] [Related]
35. Good manufacturing practice production of adenoviral vectors for clinical trials. Lusky M Hum Gene Ther; 2005 Mar; 16(3):281-91. PubMed ID: 15812223 [TBL] [Abstract][Full Text] [Related]
36. Early life vaccination: Generation of adult-quality memory CD8+ T cells in infant mice using non-replicating adenoviral vectors. Nazerai L; Bassi MR; Uddback IE; Holst PJ; Christensen JP; Thomsen AR Sci Rep; 2016 Dec; 6():38666. PubMed ID: 27929135 [TBL] [Abstract][Full Text] [Related]
37. Progress on adenovirus-vectored universal influenza vaccines. Xiang K; Ying G; Yan Z; Shanshan Y; Lei Z; Hongjun L; Maosheng S Hum Vaccin Immunother; 2015; 11(5):1209-22. PubMed ID: 25876176 [TBL] [Abstract][Full Text] [Related]
38. Adenoviruses as vectors for HIV vaccines. Gómez-Román VR; Robert-Guroff M AIDS Rev; 2003; 5(3):178-85. PubMed ID: 14598567 [TBL] [Abstract][Full Text] [Related]
39. Process optimization and scale-up for production of rabies vaccine live adenovirus vector (AdRG1.3). Shen CF; Lanthier S; Jacob D; Montes J; Beath A; Beresford A; Kamen A Vaccine; 2012 Jan; 30(2):300-6. PubMed ID: 22079076 [TBL] [Abstract][Full Text] [Related]
40. Lactococcus lactis-based vaccines from laboratory bench to human use: an overview. Bahey-El-Din M Vaccine; 2012 Jan; 30(4):685-90. PubMed ID: 22154771 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]